Biosimilars – Corporate Strategies – Reference Brand Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the generics sector, there are limited examples that innovator companies can rely on to assess the future impact of biosimilars on their products or that biosimilar companies can depend on to size their opportunities. However, successful strategies have emerged: there are strategic partnerships between biosimilars developers to complement manufacturing capabilities and bridge knowledge gaps in the regulatory and marketing landscape, and innovator companies have implemented pricing and innovation strategies to manage loss of exclusivity across their biologic portfolios.
Questions answered
- How have biosimilars developers achieved success in the biosimilars market?
- What options are available to biosimilars developers that lack in-house manufacturing capabilities?
- What factors should biosimilars developers consider when designing biosimilar clinical programs?
- How can biosimilar and reference brand companies exploit the multifactorial decision-making process used by stakeholders to differentiate their product from the competition?
- What types of data do physicians require to increase their use of biosimilars in biologic-treated patients?
- What options are available to reference brand companies seeking to defend against biosimilar entry?
- Which biopharma companies are most at risk of biosimilar competition?
- How are the leading players seeking to defend their innovator biologics portfolios?
Key markets covered: Global
Secondary research: Company annual reports, press releases, and presentations; news articles; clinical trial registries; regulatory databases
Key analyses: How have biosimilar companies achieved success? What strategies are being developed by innovator companies to remain competitive?
Product description
Biosimilars | Corporate Strategies provides critical competitive intelligence as well as actionable recommendations on how to achieve market success by providing a wider view of potential strategies used by both the reference brand and biosimilars developers to defend and maximize the market share of their respective products. In addition, it covers the details of the deals and partnerships that are performed by these companies to complement manufacturing capabilities and bridge knowledge gaps in the regulatory and marketing landscape.
